Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
22 hedge funds and large institutions have $11.5M invested in Interpace Biosciences, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 4 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
25% more capital invested
Capital invested by funds: $9.16M → $11.5M (+$2.29M)
4% less funds holding
Funds holding: 23 → 22 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$494K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$246K |
| 3 |
ANTB
AMG National Trust Bank
Greenwood Village,
Colorado
|
+$13.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.89K |
| 5 |
Renaissance Technologies
New York
|
+$6.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
Pekin Hardy Strauss
Chicago,
Illinois
|
-$285K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$17K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$11.6K |
IDXG Hedge Fund Activity: Q3 2015 in Review
22 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2015, worth a combined $11.5M — up 25% from $9.16M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IDXG and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 9 added.
The largest buyer was Heartland Advisors, adding an estimated $494K. The largest seller was Pekin Hardy Strauss, exiting entirely with an estimated $285K sold.
- 22 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2015, down from 23 in Q2 2015.
- Funds reported $11.5M of Interpace Biosciences, Inc. Common Stock stock for Q3 2015, up 25% quarter-over-quarter.
- 3 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2015 and 4 closed out, a net change of -1 holder.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2015 was Heartland Advisors, an estimated $494K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2015 was Pekin Hardy Strauss, an estimated $285K sold.
Based on aggregated 13F filings for Q3 2015.